_version_ 1784581064045363200
author TEMESGEN, ZELALEM
BURGER, CHARLES
BAKER, JASON
POLK, CHRISTOPHER
LIBERTIN, CLAUDIA
KELLEY, COLLEEN
MARCONI, VINCENT
ORENSTEIN, ROBERT
CATTERSON, VICTORIA
ARONSTEIN, WILLIAM
DURRANT, CAMERON
CHAPPELL, DALE
CHAPPELL, GABRIELLE
AHMED, OMAR
BADLEY, ANDREW
author_facet TEMESGEN, ZELALEM
BURGER, CHARLES
BAKER, JASON
POLK, CHRISTOPHER
LIBERTIN, CLAUDIA
KELLEY, COLLEEN
MARCONI, VINCENT
ORENSTEIN, ROBERT
CATTERSON, VICTORIA
ARONSTEIN, WILLIAM
DURRANT, CAMERON
CHAPPELL, DALE
CHAPPELL, GABRIELLE
AHMED, OMAR
BADLEY, ANDREW
author_sort TEMESGEN, ZELALEM
collection PubMed
description
format Online
Article
Text
id pubmed-8503207
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American College of Chest Physicians. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85032072021-10-12 C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL TEMESGEN, ZELALEM BURGER, CHARLES BAKER, JASON POLK, CHRISTOPHER LIBERTIN, CLAUDIA KELLEY, COLLEEN MARCONI, VINCENT ORENSTEIN, ROBERT CATTERSON, VICTORIA ARONSTEIN, WILLIAM DURRANT, CAMERON CHAPPELL, DALE CHAPPELL, GABRIELLE AHMED, OMAR BADLEY, ANDREW Chest Late Breaking American College of Chest Physicians. Published by Elsevier Inc. 2021-10 2021-10-11 /pmc/articles/PMC8503207/ http://dx.doi.org/10.1016/j.chest.2021.08.029 Text en Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Late Breaking
TEMESGEN, ZELALEM
BURGER, CHARLES
BAKER, JASON
POLK, CHRISTOPHER
LIBERTIN, CLAUDIA
KELLEY, COLLEEN
MARCONI, VINCENT
ORENSTEIN, ROBERT
CATTERSON, VICTORIA
ARONSTEIN, WILLIAM
DURRANT, CAMERON
CHAPPELL, DALE
CHAPPELL, GABRIELLE
AHMED, OMAR
BADLEY, ANDREW
C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title_full C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title_fullStr C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title_full_unstemmed C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title_short C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
title_sort c-reactive protein as a biomarker for improved efficacy of lenzilumab in patients with covid-19: results from the live-air trial
topic Late Breaking
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207/
http://dx.doi.org/10.1016/j.chest.2021.08.029
work_keys_str_mv AT temesgenzelalem creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT burgercharles creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT bakerjason creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT polkchristopher creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT libertinclaudia creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT kelleycolleen creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT marconivincent creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT orensteinrobert creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT cattersonvictoria creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT aronsteinwilliam creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT durrantcameron creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT chappelldale creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT chappellgabrielle creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT ahmedomar creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial
AT badleyandrew creactiveproteinasabiomarkerforimprovedefficacyoflenzilumabinpatientswithcovid19resultsfromtheliveairtrial